Erika Hamilton, MD / Yelena Y. Janjigian, MD / Sandip Patel, MD / Nikhil Wagle, MD / - Moving in Leaps and Bounds Toward Expanded Precision Treatment of HER2- or HER3-Driven Breast, Gastrointestinal, Lung, and Other Cancers: Current Challenges, Opportunities for Improvement, and Practical Considerations

Go online to PeerView.com/VJP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, oncology experts explore the potential of the next wave of novel HER2-targeting therapies in various HER2-altered cancers, including breast, gastrointestinal, lung, and other tumors. Watch as the panel share their insights into the data that support therapeutic targeting of HER2 and consider other critical research questions and future directions. Upon completion of this activity, participants should be better able to: Review evidence-based guidelines and expert recommendations regarding HER2 testing and interpretation of results in breast, gastric, colorectal, and non–small cell lung cancers, Evaluate the characteristics, mechanisms of action, and efficacy/safety evidence of established and emerging HER2-targeted agents for the management of patients with advanced HER2-expressing or ERBB2-mutant cancers, Identify novel approaches to overcome mechanisms of resistance to HER2-targeted therapies, Integrate the latest HER2-targeted therapies into individualized treatment plans for patients with advanced HER2-expressing or ERBB2-mutant breast, gastric, colorectal, and non–small cell lung cancers, either in the context of clinical practice or through clinical trial participation.